News | August 30, 2021
Acute therapies drive overall pharma growth in July: Ind-Ra
The segment delivered strong sales growth of 20% YoY
The segment delivered strong sales growth of 20% YoY
Founded by Amit Patni, the company rolls out 90+ formulations across acute and specialty therapies
Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
Ind-Ra expects FY22 IPM to have witnessed 15% YoY sales growth, higher than the 8%-10% observed over the past five years, aided by the base effect
The stability is led by healthy demand in the domestic and emerging markets
Ind-Ra expects revenue growth of over 12% in 2022.
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Flattish volume growth and subdued new launches were key factors for last month
_256_384.jpg)
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
Subscribe To Our Newsletter & Stay Updated
